Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Quarterly Earnings Results, Misses Expectations By $0.14 EPS

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) announced its earnings results on Thursday. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.14), FiscalAI reports.

Zentalis Pharmaceuticals Stock Performance

Zentalis Pharmaceuticals stock traded up $0.05 during mid-day trading on Thursday, hitting $5.00. The company’s stock had a trading volume of 701,420 shares, compared to its average volume of 1,175,629. The company has a 50 day moving average of $4.31 and a 200-day moving average of $3.59. The stock has a market cap of $355.95 million, a PE ratio of -2.89 and a beta of 1.92. Zentalis Pharmaceuticals has a one year low of $1.21 and a one year high of $6.95.

Get Zentalis Pharmaceuticals alerts:

Institutional Trading of Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Millennium Management LLC grew its holdings in shares of Zentalis Pharmaceuticals by 220.6% in the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after purchasing an additional 2,111,951 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Zentalis Pharmaceuticals by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock valued at $4,386,000 after buying an additional 19,768 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Zentalis Pharmaceuticals by 24.0% during the 4th quarter. Renaissance Technologies LLC now owns 2,883,745 shares of the company’s stock valued at $3,893,000 after buying an additional 558,390 shares in the last quarter. Bank of America Corp DE boosted its position in Zentalis Pharmaceuticals by 117.1% in the 3rd quarter. Bank of America Corp DE now owns 1,548,781 shares of the company’s stock valued at $2,339,000 after buying an additional 835,466 shares during the period. Finally, Opaleye Management Inc. boosted its position in Zentalis Pharmaceuticals by 342.6% in the 4th quarter. Opaleye Management Inc. now owns 1,400,906 shares of the company’s stock valued at $1,891,000 after buying an additional 1,084,356 shares during the period.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. Rodman & Renshaw started coverage on shares of Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They issued a “buy” rating and a $11.00 target price for the company. Mizuho started coverage on shares of Zentalis Pharmaceuticals in a report on Friday, July 17th. They issued an “outperform” rating and a $8.00 target price for the company. Finally, Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 31st. Four research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $6.75.

Check Out Our Latest Analysis on Zentalis Pharmaceuticals

About Zentalis Pharmaceuticals

(Get Free Report)

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.

Read More

• Five stocks we like better than Zentalis Pharmaceuticals
• Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
• 4 Oil and Gas ETF Plays as Prices Stay Sky-High
• What Tesla Stands to Lose If It Walks Away From China
• Disney Sets Up for a Magical Year in 2027

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.